Preferred Label : Evorpacept;
NCIt synonyms : SIRPa Variant ALX148; CD47/SIRPa-blocking Agent ALX148; LGGL-ALX-148; CD47 Antagonist ALX148;
NCIt definition : A variant of signal regulatory protein alpha (SIRPa) that antagonizes the human cell
surface antigen CD47, with potential phagocytosis-inducing, immunostimulating and
antineoplastic activities. Upon administration, evorpacept binds to CD47 expressed
on tumor cells and prevents the interaction of CD47 with its ligand SIRPa, a protein
expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates
the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling
mediated by the binding of the pro-phagocytic signal calreticulin (CRT), which is
specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL)
receptor-related protein (LRP), expressed on macrophages. This results in macrophage
activation and the specific phagocytosis of tumor cells. In addition, blocking CD47
signaling activates both an anti-tumor cytotoxic T-lymphocyte (CTL) immune response
and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated
protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic
stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression
of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation
and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.;
UNII : X7K762X1IJ;
CAS number : 2484949-51-9;
Molecule name : ALX 148; ALX-148;
NCI Metathesaurus CUI : CL519706;
Origin ID : C132851;
UMLS CUI : C5667161;
Currated CISMeF NLP mapping
- ALX148 [MeSH Supplementary Concept]
- Semantic type(s)
- UMLS correspondences (same concept)
- ALX148 [MeSH Supplementary Concept]
- concept_is_in_subset
- has_target
